Mustbio raises KRW 16.5 billion in Series B to develop multispecific antibodies (Biospectator, 2022.12.08) Date2022-12-30 View529 http://www.biospectator.com/view/news_view.php?varAtcId=17837 Prev [Notice] New stock issuance (2022.11.15) Next Solid PoC data required to attract biotech investment (Hitnews, 2023.01.02) back to list
